Prediction of premature ovarian insufficiency: foolish fallacy or feasible foresight?

References

• Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019;22:403–11
   PubMed Web of Science ®Google Scholar
• Tucker EJ, Grover SR, Bachelot A, Touraine P, Sinclair AH. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum. Endocr Rev 2016;37:609–35
   PubMed Web of Science ®Google Scholar
• Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric 2016;19:27–36
   PubMed Web of Science ®Google Scholar
• Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016;31:926–37
   PubMed Web of Science ®Google Scholar
• Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an international menopause society white paper. Climacteric 2020;23:426–46
   PubMed Web of Science ®Google Scholar
• Jiao X, Ke H, Qin Y, Chen ZJ. Molecular genetics of premature ovarian insufficiency. Trends Endocrinol Metab 2018;29:795–807
   PubMed Web of Science ®Google Scholar
• Patiño LC, Beau I, Carlosama C, et al. New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Hum Reprod 2017;32:1512–20
   PubMed Web of Science ®Google Scholar
• Sykiotis GP, Plummer L, Hughes VA, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA 2010;107:15140–4
   PubMed Web of Science ®Google Scholar
• Richardson MC, Guo M, Fauser BC, Macklon NS. Environmental and developmental origins of ovarian reserve. Hum Reprod Update 2014;20:353–69
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83
   PubMed Web of Science ®Google Scholar
• Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19:519–27
   PubMed Web of Science ®Google Scholar
• Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996;17:121–55
   PubMed Web of Science ®Google Scholar
• Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011;95:170–5
   PubMed Web of Science ®Google Scholar
• Kevenaar ME, Meerasahib MF, Kramer P, et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006;147:3228–34
   PubMed Web of Science ®Google Scholar
• von Wolff M, Roumet M, Stute P, Liebenthron J. Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. Maturitas 2020;134:34–40
   PubMed Web of Science ®Google Scholar
• Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One 2011;6:e22024
   PubMed Web of Science ®Google Scholar
• Fleming R, Kelsey TW, Anderson RA, Wallace WH, Nelson SM. Interpreting human follicular recruitment and antimüllerian hormone concentrations throughout life. Fertil Steril 2012;98:1097–102
   PubMed Web of Science ®Google Scholar
• van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008;93:2129–34
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Solaymani-Dodaran M, Azizi F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause 2009;16:797–802
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab 2013;98:729–35
   PubMed Web of Science ®Google Scholar
• Depmann M, Eijkemans MJC, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. J Clin Endocrinol Metab 2017;100:201 Online ahead of print
   Google Scholar
• Finkelstein JS, Lee H, Karlamangla A, et al. Antimullerian hormone and impending menopause in late reproductive age: The Study of Women’s Health Across the Nation. J Clin Endocrinol Metab 2020;105:e1862–e71
   Web of Science ®Google Scholar
• Soares AG, Kilpi F, Fraser A, et al. Longitudinal changes in reproductive hormones through the menopause transition in the Avon Longitudinal Study of Parents and Children (ALSPAC). Sci Rep 2020;10:21258
   PubMed Web of Science ®Google Scholar
• van Rooij IA, Tonkelaar I, Broekmans FJ, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004;11:601–6
   PubMedGoogle Scholar
• Kim C, Slaughter JC, Wang ET, et al. Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas 2017;102:18–25
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-Mullerian hormone levels and incidence of early natural menopause in a prospective study. Hum Reprod 2018;33:1175–82
   PubMed Web of Science ®Google Scholar
• de Kat AC, van der Schouw YT, Eijkemans MJC, Broer SL, Verschuren WMM, Broekmans FJM. Can menopause prediction be improved with multiple AMH measurements? Results from the prospective Doetinchem Cohort Study. J Clin Endocrinol Metab 2019;104:5024–31
   PubMed Web of Science ®Google Scholar
• Lunding SA, Aksglaede L, Anderson RA, et al. AMH as predictor of premature ovarian insufficiency: a longitudinal study of 120 Turner syndrome patients. J Clin Endocrinol Metab 2015;100:E1030–8
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Lin H, Boorman DW, Gracia CR. Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril 2012;98:1254–9 e1-2
   PubMed Web of Science ®Google Scholar
• Ramezani Tehrani F, Bidhendi Yarandi R, Solaymani-Dodaran M, Tohidi M, Firouzi F, Azizi F. Improving prediction of age at menopause using multiple anti-mullerian hormone measurements: the tehran lipid-glucose study. J Clin Endocrinol Metab 2020;105:dgaa083
   PubMed Web of Science ®Google Scholar
• Fauser B, Nelson SM. Next steps toward AMH as a robust biomarker for assessing ovarian aging in individual women. J Clin Endocrinol Metab 2020;105:e2643–4
   Web of Science ®Google Scholar
• Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z. Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet 2016;33:657–62
   PubMed Web of Science ®Google Scholar
• Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013;137:571–7
   PubMed Web of Science ®Google Scholar
• Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336–43
   PubMed Web of Science ®Google Scholar
• Barnabei A, Strigari L, Marchetti P, et al. Predicting ovarian activity in women affected by early breast cancer: a meta-analysis-based nomogram. Oncologist 2015;20:1111–18
   PubMed Web of Science ®Google Scholar
• Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013;49:3404–11
   PubMed Web of Science ®Google Scholar
• Xue C, Wei W, Sun P, et al. Pretreatment anti-mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res Treat 2019;173:619–28
   PubMed Web of Science ®Google Scholar
• Li X, Liu S, Ma L, et al. Can anti-müllerian hormone be a reliable biomarker for assessing ovarian function in women postchemotherapy? CMAR 2020;12:8171–81
   Web of Science ®Google Scholar
• Cameron K, Sammel MD, Prewitt M, Gracia C. Differential rates of change in measures of ovarian reserve in young cancer survivors across the reproductive lifespan. J Clin Endocrinol Metab 2019;104:1813–22
   PubMed Web of Science ®Google Scholar
• Su HI, Kwan B, Whitcomb BW, et al. Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH. J Clin Endocrinol Metab 2020;105:2740–51
   Web of Science ®Google Scholar
• Younis JS, Shapso N, Fleming R, Ben-Shlomo I, Izhaki I. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Reprod Update 2019;25:375–91
   PubMed Web of Science ®Google Scholar